As Wnt4 may signal via both the canonical/β-catenin pathway and non-canonical pathways (23–25), we used the tankyrase inhibitor XAV939 to ascertain whether β-catenin-mediated signalling is involved in MD development (26). The gene discussed is WNT4; the disease is Menkes disease.